Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Hepatitis
AI in study enables better RT-LAMP, CRISPR tests
Artificial intelligence, CRISPR, and RT-LAMP technologies are helping developers create simple, reliable tests for hepatitis C and COVID-19 for eventual at-home use.
May 8, 2023
Researchers in Spain demonstrate HCV RNA detection, genotyping using dried blood spot samples
The research shows the potential of using dried blood spot samples for determining cure rates and differentiating between reinfection and relapse after antiviral treatment in people who inject drugs.
March 20, 2023
National hepatitis C elimination program represents an historic opportunity, according to White House
The Biden-Harris administration proposes a five-year program to expand screening, testing, treatment, and prevention of hepatitis C, focusing on high-risk populations.
March 14, 2023
Roche launches antigen, antibody hepatitis C test
Elecsys HCV Duo uses plasma or blood samples and allows for earlier diagnosis of active hepatitis C infection -- which in turn improves patient care by helping sufferers of the disease get earlier treatment, according to the firm.
July 17, 2022
Lucence promotes study of LiquidHallmark biopsy assay
LiquidHallmark is an amplicon-based next-generation sequencing assay developed for the genomic profiling of plasma-derived cell-free DNA (cfDNA). The 80-gene panel profiles point mutations, insertions/deletions, copy number alterations, and gene fusions, and further detects oncogenic viruses (Epstein-Barr virus [EBV] and hepatitis B virus [HBV]) and microsatellite instability (MSI), according to the company.
May 18, 2022
Co-Diagnostics joint venture approved for HCV test in India
Co-Diagnostics said its joint venture in India, CoSara Diagnostics, has received clearance to manufacture and sell its Saraq Hepatitis C (HCV) Viral Load Kit as an in vitro diagnostic.
April 18, 2022
Hologic adds SARS-CoV-2 test to global testing project
Hologic launched GAI at the 2018 International AIDS Conference as an initiative to offer an all-inclusive pricing structure with no upfront cost or capital expenditure. In addition to the SARS-CoV-2 assay, the company offers other tests in the initiative, including tests for HIV-1, hepatitis B and C, and HPV.
January 4, 2022
Roche launches test on new Cobas 5800 lab system
The following Cobas tests can run on the new compact system:
December 14, 2021
How pathologists act as 'firefighters' during COVID-19
Especially in the early stages of the pandemic, there were numerous unknowns about how to proceed with autopsies because COVID-19 was an unknown disease. What type of infectious disease was it? Was it like tuberculosis, HIV, hepatitis C, or mad cow disease?
October 3, 2021
Thermo Fisher debuts infectious disease quality controls
The Thermo Scientific Mas Omni Infectious positive and negative quality controls are third-party, independent external controls used to assess the performance of serological assays for HIV types 1 and 2, hepatitis B and C, syphilis, and human T-cell leukemia virus types 1 and 2. Monitoring the assays' performance can streamline operations and may reduce spending without sacrificing quality, according to the company.
June 30, 2020
Study calls for hepatitis D screening in at-risk patients
A review of the literature suggests that those who have hepatitis D along with hepatitis B have up to three times the risk for developing hepatocellular carcinoma than if they had hepatitis B alone, reported researchers at the University of Geneva and Geneva University Hospitals, in an article in press. This assessment was based on an analysis of data from 93 studies including a total of more than 100,000 patients.
May 19, 2020
USPSTF's broad backing of hepatitis C testing comes as a welcome change
The task force published a final recommendation statement and evidence report on March 2, assigning a B recommendation for screening -- meaning there is high certainty of a net benefit -- in this broad population. The group also urged consideration of testing for people younger than 18 and older than 79, if appropriate. The guidance is in line with draft recommendations published in August.
March 3, 2020
Page 1 of 2
Next Page
